Royalty Pharma (RPRX) Goodwill (2025 - 2026)

Royalty Pharma's (RPRX) quarterly Goodwill came in at $924.6 million in Q1 2026, little changed quarter-over-quarter from $924.6 million in Q4 2025.

Royalty Pharma (RPRX) Goodwill (2025 - 2026) Analysis & Trends

Royalty Pharma has disclosed Goodwill across 2 years of filings, most recently posting $924.6 million for Q1 2026.

Goodwill for Q1 2026 came in at $924.6 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $924.6 million (changed N/A YoY), and the FY2025 annual result was $924.6 million, changed N/A from the prior year.
Goodwill came in at $924.6 million for Q1 2026 at Royalty Pharma, roughly flat from $924.6 million in the prior quarter.
In the past five years, Goodwill ranged from a high of $924.6 million in Q2 2025 to a low of $924.6 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Royalty Pharma	23.13 Bn	25.57 Bn	-

Download Data